Healthcare Economics — Asia-Pacific | NovaPharmaNews

Breaking

European Research Revolution: Day 1 Highlights RAPS Euro Convergence: Key Regulatory Updates - Day 1 Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD

PSG 2026 Specialty Drug Benefits Report: Cost Management Remains Top Priority as Coverage Strategies Challenge Payers

NewsApr 28, 2026

PSG 2026 Specialty Drug Benefits Report: Cost Management Remains Top Priority as Coverage Strategies Challenge Payers

PSG's 13th annual report reveals payers prioritize cost management while struggling with coverage strategies for new specialty drugs and indications.